<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432885</url>
  </required_header>
  <id_info>
    <org_study_id>1095/08</org_study_id>
    <nct_id>NCT02432885</nct_id>
  </id_info>
  <brief_title>Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial</brief_title>
  <official_title>Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>InCor Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial intends to evaluate myocardial Fibrosis progression in Duchenne and Becker
      Muscular Dystrophy, as well the influence of ACE inhibitors in fibrosis progression.
      Additionally, this study aims to determine genetic predictors of cardiac involvement in these
      dystrophies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Duchenne and Becker muscular dystrophies (DMD/BMD) are diseases characterized by progressive
      skeletal muscle degeneration and replacement by fibrofatty tissue. Data on cardiac
      involvement (defined as myocardial fibrosis), effect of ACE-inhibitors and specific genetic
      mutations on myocardial involvement detected by cardiac magnetic resonance (CMR) is lacking.

      The study will include 76 patients with DMD/BMD. All patients will be referred to two CMRs
      for assessment of ventricular function and myocardial fibrosis. Patients with myocardial
      fibrosis and normal left ventricle ejection fraction (LVEF) will be randomized into two
      groups, each group receiving ACE-inhibitor treatment or no treatment for cardiomyopathy. A
      genetic profile will be performed in every patient to identify possible mutations related to
      cardiac involvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative Myocardial Fibrosis by CMR in patients with and without ACE inhibitor therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Progression of myocardial fibrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specific genetic mutations as predictors of cardiac involvement</measure>
    <time_frame>2 years</time_frame>
    <description>Relation of dystrophin gene site mutations in exons &lt;45 relation and the extent of myocardial fibrosis measured by cardiac magnetic resonance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Myocardial Fibrosis</condition>
  <condition>Muscular Dystrophies</condition>
  <arm_group>
    <arm_group_label>ACE inhibitor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>up to 20mg bid</description>
    <arm_group_label>ACE inhibitor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy-proven Muscular Dystrophy of Duchenne or Becker

        Exclusion Criteria:

          -  Contraindications to cardiovascular magnetic resonance imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos E Rochitte, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor, Heart Institute, University of Sao Paulo Medical School</affiliation>
  </overall_official>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>May 1, 2015</last_update_submitted>
  <last_update_submitted_qc>May 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>InCor Heart Institute</investigator_affiliation>
    <investigator_full_name>Carlos Eduardo Rochitte</investigator_full_name>
    <investigator_title>Associate Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>cardiac magnetic resonance</keyword>
  <keyword>myocardial fibrosis</keyword>
  <keyword>muscular dystrophies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

